Is Tesa Out of the Game? CBL-514 Steps In as the New Tesa

A manufacturer statement was put out in Milan earlier this month, and I'll share it here. From what I've dug up on my own, this drug wipes out fat cells to a degree that weight coming back on—something that tends to happen once GLP-1 treatment ends—gets blocked pretty effectively.

Put another way, it might work as something you stay on long term. Personally, I think it's definitely worth looking at as another route to work into my routine.



www.caliwaybiopharma.com

EASD Press Room Features New Data on CBL-514 for Reducing Subcutaneous and Visceral Fat-Caliway Biopharmaceuticals Co., Ltd

Studies show that the new drug, CBL-514, reduces levels of subcutaneous and visceral fat. The data also suggest that it helps attenuate weight regain on stopping GLP-1 receptor agonist drugs (GLP1-RAs), says Dr W. Timothy Garvey, of the University of Alabama at Birmingham, Birmingham, USA.
www.caliwaybiopharma.com www.caliwaybiopharma.com
 
Interesting. From the looks of it, the injection is placed in a grid pattern over the treatment area, rather than being taken the way a typical peptide would be.
 
lessthanhalf said:

Honestly, that's kind of amusing — the studies dosed 600mg/day while each vial holds only 20mg, meaning you'd need 30 vials, likely quite pricey ones, just to cover a single day's dose.

My curiosity got piqued when I noticed SANA being sold on ebay. It works by activating futile creatine cycling to burn off energy, similar to a mitochondrial uncoupling agent such as bam15 or DNP, except through a novel and distinct mechanism. It even has phase 1 human trials, which puts it ahead of a large share of peptides. That said, the doses were 600mg/day and 5 grams runs about $100 usd ( on ebay ), so purely on cost grounds it isn't really workable ( $100 for 8 days worth ) — that is, if you're willing to take something backed only by phase 1 data. It's nearly as expensive as non grey GLP's. Even so, it's probably a safer bet than bam15 and unquestionably safer than DNP. Oddly enough, despite its track record, they are seriously working on a prodrug form of DNP that gets converted into DNP in the liver, so its effects stay more localised, the doses reaching the body overall are far lower, and presumably the odds of killing you drop as well.
Click to expand...
Based on what those articles describe, the schedule appears to be 600mg once every three weeks — not a daily dose.
 
Here it's being pitched as something that might stand in for cosmetic surgery among people who aren't obese. That doesn't mean it takes the place of tirz.



Efficacy and Safety of CBL-514 Injection in Reducing Abdominal Subcutaneous Fat: A Randomized, Single-Blind, Placebo-Controlled Phase II Study - PMC

A small-molecule injectable drug, CBL-514, has shown promising efficacy and safety for subcutaneous fat reduction. To further evaluate the efficacy and safety of CBL-514 for abdominal subcutaneous fat reduction. In this single-blind, randomized, ...
pmc.ncbi.nlm.nih.gov pmc.ncbi.nlm.nih.gov
 
loppsy said:

Based on what those articles describe, the schedule appears to be 600mg once every three weeks — not a daily dose.
Click to expand...
Appreciate the info. I had believed the dosages came from the original rat trial, yet I'm unable to locate it now. In the phase 2 human trial, though, the amount went as high as 600mg, delivered as many small injections locally to cut fat in one spot, essentially a gentler form of liposuction. What's confusing is that they're simultaneously looking at systemic effects, and in those very patients they recorded roughly a 10% decrease in measured visceral fat. There was also a rat experiment where it was given alongside tirzepatide, and those rats shed more weight than with tirz alone while regaining less after treatment ended. It's strange to watch a drug being developed that performs 2 separate actions requiring independent study: destroying fat cells locally right where it's injected, and at the same time producing a smaller yet potentially more meaningful impact on visceral fat cells elsewhere. Since it eliminates cells by triggering death pathways that cause apoptosis, you'd want extremely strong proof that it isn't switching on those same pathways in other cell types.

Even so, dosing every 3 weeks at $220 per 20mg (I believe that's per vial, not per 10 vials - purepeptidefactory) works out to $6600 per dose to treat a small localized patch of subcutaneous fat, with perhaps a slight visceral fat reduction on the side, which seems rather impractical.
 
lessthanhalf said:

Appreciate the info. I had believed the dosages came from the original rat trial, yet I'm unable to locate it now. In the phase 2 human trial, though, the amount went as high as 600mg, delivered as many small injections locally to cut fat in one spot, essentially a gentler form of liposuction. What's confusing is that they're simultaneously looking at systemic effects, and in those very patients they recorded roughly a 10% decrease in measured visceral fat. There was also a rat experiment where it was given alongside tirzepatide, and those rats shed more weight than with tirz alone while regaining less after treatment ended. It's strange to watch a drug being developed that performs 2 separate actions requiring independent study: destroying fat cells locally right where it's injected, and at the same time producing a smaller yet potentially more meaningful impact on visceral fat cells elsewhere. Since it eliminates cells by triggering death pathways that cause apoptosis, you'd want extremely strong proof that it isn't switching on those same pathways in other cell types.

Even so, dosing every 3 weeks at $220 per 20mg (I believe that's per vial, not per 10 vials - purepeptidefactory) works out to $6600 per dose to treat a small localized patch of subcutaneous fat, with perhaps a slight visceral fat reduction on the side, which seems rather impractical.
Click to expand...
At this point, IMO, these 2 things matter most.

Even grey users, who generally accept more risk than the average person, will likely still need some solid reassurance that the mechanism responsible for destroying fat cells isn't going to destroy other things indiscriminately.

Should the pricing turn out to be $220/20mg x 10 kit rather than $220/20mg vial, interest would pick up (despite that being steep for grey), but if it stays at $220/20mg, it's basically finished outside of the genuinely wealthy… who already have easier ways to spot reduce subq fat.
 
faloppi said:


Just saw that Joyous is running a GB on this, $325 for a kit of 50mg vials, will include testing from Jano and Jano thinks they have enough info to verify. I'm personally not interested in using but pretty amazed this is being produced already (accurately remains to be seen which is most important of course), but definitely will be watching from the sidelines out of curiosity!

Click to expand...
Click to expand...
As for the amount, a 50 mg × 10 set seems reasonable for the initial 3 weeks. That said, getting the dosing exactly right would definitely make this an intriguing — if difficult — experiment to set up.
 
To me, it seems far too simple for a shady provider to pass off something like adipotide while calling it CBL-514. It brings back memories of the bioglutide hype from a couple of years back. Without a COA, I wouldn't touch it — particularly not from a peptide vendor advertising 'Made in the USA'.
 
faloppi said:


Just saw that Joyous is running a GB on this, $325 for a kit of 50mg vials, will include testing from Jano and Jano thinks they have enough info to verify. I'm personally not interested in using but pretty amazed this is being produced already (accurately remains to be seen which is most important of course), but definitely will be watching from the sidelines out of curiosity!

Click to expand...
Click to expand...
I noticed it as well. I wasn't sure what it was until I came across this thread.
 
Given the reports of tissue issues and the fact that treatment has to be so precisely targeted, I figure I'll hold off on it for now.
 
Back
Top